BREN-02, a lab-made form of the human protein engrailed 1 (EN1), has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) as a potential treatment of amyotrophic lateral sclerosis…
The Stentrode, a minimally invasive, fully implanted wireless device that transmits signals from the brain’s motor cortex, can help people with upper limb paralysis control a digital device without using their hands, a study shows. In a first-in-human experience, the device…
A newly identified type of immune cell — a kind of immature neurophil or white blood cell — was found to be responsible for the regeneration and survival of eye and spinal cord nerve fibers that is known to be possible in mice with induced nerve injury,…
Most people with bulbar onset amyotrophic lateral sclerosis (ALS) showed distinct signs of motor neuron injury starting in the bulbar region of the brain that controls swallowing and speaking, before symptoms descended to regions that control the upper limbs and then the lower…
BrainStorm Cell Therapeutics is sharing the details of the design of its Phase 3 clinical trial evaluating NurOwn as a treatment for people with rapidly progressing amyotrophic lateral sclerosis (ALS), showing that the trial is…
The Muscular Dystrophy Association (MDA) has awarded five new grants totaling more than $1.6 million to boost research of amyotrophic lateral sclerosis (ALS). These grants add to the $168 million already donated to ALS research by…
Saphyr, an ultra-long DNA analysis technology by Bionano Genomics, is the first to successfully measure very large repeat expansions in the C9ORF72 gene, the underlying cause of some amyotrophic lateral sclerosis (ALS) cases, the…
A combined analysis using people of Japanese, Chinese, and European ancestry identified five new genes associated with the non-familial, sporadic form of amyotrophic lateral sclerosis (ALS). These findings further an understanding of the genetic basis of sporadic ALS, and may support…
Aural Analytics’ speech-based digital technology will be used to measure changes in speech in people with amyotrophic lateral sclerosis (ALS) as endpoints for the HEALEY ALS Platform Trial, which is evaluating multiple potential ALS treatments…
Stem cells collected from a patient’s bone marrow and infused into the spinal fluid safely improved speaking abilities after 28 days for most of the 12 adults with amyotrophic lateral sclerosis (ALS) evaluated in a small study. Its researchers recommend further…
Get regular updates to your inbox.